Pelargonidin Alleviates Acrolein-induced Inflammation in Human Umbilical Vein Endothelial Cells by Reducing COX-2 Expression Through the NF-κB Pathway

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2023 Sep 20

PMID 37728621

Authors

Youping Wan

Han Yang

Guoping Zhang

Affiliations

Soon will be listed here.

Abstract

Acrolein, a common environmental pollutant, is linked to the development of cardiovascular inflammatory diseases. Pelargonidin is a natural compound with anti-inflammation activity. In this study, we aimed to explore the effects of pelargonidin on inflammation induced by acrolein in human umbilical vein endothelial cells (HUVECs). MTT assay was utilized for assessing cell viability in HUVECs. LDH release in HUVECs was measured using the LDH kit. Western blot was used to detect the protein expression of p-p65, p65 and COX-2. Inflammation was evaluated through determining the levels of PGE2, IL-1β, IL-6, IL-8 and TNF-α in HUVECs after treatment. COX-2 mRNA expression and COX-2 content were examined using RT-qPCR and a human COX-2 ELISA kit, respectively. Acrolein treatment at 50 μM resulted in a 45% decrease in the viability and an increase in LDH release (2.2-fold) in HUVECs. Pelargonidin at 5, 10, 20, and 40 μM alleviated acrolein-caused inhibitory effect on cell viability (increased to 1.3-, 1.5-, 1.8-, and 1.9-fold, respectively, compared to acrolein treatment group) and promoting effect on LDH release (decreased to 82%, 75%, 62%, and 58%, respectively, compared to acrolein treatment group) in HUVECs. Moreover, pelargonidin or pyrrolidine dithiocarbamate (PDTC; an NF-κB pathway inhibitor) inhibited acrolein-induced activation of the NF-κB pathway. Acrolein elevated the levels of PGE2, IL-1β, IL-6, IL-8 and TNF-α (from 40.2, 27.3, 67.2, 29.0, 24.8 pg/mL in control group to 224.0, 167.3, 618.3, 104.6, and 275.1 pg/mL in acrolein treatment group, respectively), which were retarded after pelargonidin (decreased to 134.8, 82.3, 246.2, 70.2, and 120.8 pg/mL in acrolein + pelargonidin treatment group) or PDTC (decreased to 107.9, 80.1, 214.6, 64.0, and 96.6 pg/mL in acrolein + PDTC treatment group) treatment in HUVECs. Pelargonidin inactivated the NF-κB pathway to reduce acrolein-induced COX-2 expression. Furthermore, pelargonidin relieved acrolein-triggered inflammation through decreasing COX-2 expression by inactivating the NF-κB pathway in HUVECs. In conclusion, pelargonidin could protect against acrolein-triggered inflammation in HUVECs through attenuating COX-2 expression by inactivating the NF-κB pathway.

References

Buchweitz M, Speth M, Kammerer D, Carle R . Impact of pectin type on the storage stability of black currant (Ribes nigrum L.) anthocyanins in pectic model solutions. Food Chem. 2013; 139(1-4):1168-78. DOI: 10.1016/j.foodchem.2013.02.005. View

Chen W, Zhang J, Ghare S, Barve S, McClain C, Joshi-Barve S . Acrolein Is a Pathogenic Mediator of Alcoholic Liver Disease and the Scavenger Hydralazine Is Protective in Mice. Cell Mol Gastroenterol Hepatol. 2017; 2(5):685-700. PMC: 5042858. DOI: 10.1016/j.jcmgh.2016.05.010. View

Cipollone F . COX-2 and prostaglandins in atherosclerosis. Lupus. 2005; 14(9):756-9. DOI: 10.1191/0961203305lu2215oa. View

Daimon M, Sugiyama K, Kameda W, Saitoh T, Oizumi T, Hirata A . Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. Endocr J. 2003; 50(1):61-7. DOI: 10.1507/endocrj.50.61. View

Duarte L, Chaves V, Nascimento M, Calvete E, Li M, Ciraolo E . Molecular mechanism of action of Pelargonidin-3-O-glucoside, the main anthocyanin responsible for the anti-inflammatory effect of strawberry fruits. Food Chem. 2017; 247:56-65. DOI: 10.1016/j.foodchem.2017.12.015. View

Ferrer M, Busquets-Cortes C, Capo X, Tejada S, Tur J, Pons A . Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases. Curr Med Chem. 2018; 26(18):3225-3241. DOI: 10.2174/0929867325666180514112124. View

Reis Geovanini G, Libby P . Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond). 2018; 132(12):1243-1252. DOI: 10.1042/CS20180306. View

Gomez-Hernandez A, Martin-Ventura J, Sanchez-Galan E, Vidal C, Ortego M, Blanco-Colio L . Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis. 2005; 187(1):139-49. DOI: 10.1016/j.atherosclerosis.2005.08.035. View

Guo L, Kang J, Kang N, Je B, Lee Y, Park Y . Pelargonidin suppresses adipogenesis in 3T3-L1 cells through inhibition of PPAR-γ signaling pathway. Arch Biochem Biophys. 2020; 686:108365. DOI: 10.1016/j.abb.2020.108365. View

10.

Hayden M, Ghosh S . Shared principles in NF-kappaB signaling. Cell. 2008; 132(3):344-62. DOI: 10.1016/j.cell.2008.01.020. View

11.

He J, Giusti M . Anthocyanins: natural colorants with health-promoting properties. Annu Rev Food Sci Technol. 2011; 1:163-87. DOI: 10.1146/annurev.food.080708.100754. View

12.

Henning R, Johnson G, Coyle J, Harbison R . Acrolein Can Cause Cardiovascular Disease: A Review. Cardiovasc Toxicol. 2017; 17(3):227-236. DOI: 10.1007/s12012-016-9396-5. View

13.

Hu W, Yang X, Zhe C, Zhang Q, Sun L, Cao K . Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-κB activation in LPS-induced RAW264.7 macrophage cells. Pharmacol Rep. 2011; 63(3):781-9. DOI: 10.1016/s1734-1140(11)70590-4. View

14.

Jeong S, Ku S, Bae J . Anti-inflammatory effects of pelargonidin on TGFBIp-induced responses. Can J Physiol Pharmacol. 2017; 95(4):372-381. DOI: 10.1139/cjpp-2016-0322. View

15.

Jiang C, Jiang L, Li Q, Liu X, Zhang T, Dong L . Acrolein induces NLRP3 inflammasome-mediated pyroptosis and suppresses migration via ROS-dependent autophagy in vascular endothelial cells. Toxicology. 2018; 410:26-40. DOI: 10.1016/j.tox.2018.09.002. View

16.

Ku S, Yoon E, Lee W, Kwon S, Lee T, Bae J . Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro. Arch Pharm Res. 2016; 39(3):398-408. DOI: 10.1007/s12272-016-0708-x. View

17.

Ladapo J, Goldfeld K, Douglas P . Projected morbidity and mortality from missed diagnoses of coronary artery disease in the United States. Int J Cardiol. 2015; 195:250-2. PMC: 4526023. DOI: 10.1016/j.ijcard.2015.05.033. View

18.

Lawrence T . The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2010; 1(6):a001651. PMC: 2882124. DOI: 10.1101/cshperspect.a001651. View

19.

Lee B, Lee C, Yang S, Park E, Ku S, Bae J . Suppressive effects of pelargonidin on lipopolysaccharide-induced inflammatory responses. Chem Biol Interact. 2019; 302:67-73. DOI: 10.1016/j.cbi.2019.02.007. View

20.

Lee I, Bae J . Suppressive effects of pelargonidin on PolyPhosphate-mediated vascular inflammatory responses. Arch Pharm Res. 2016; 40(2):258-267. DOI: 10.1007/s12272-016-0856-z. View